Dev

Mobilizing the healthcare community towards an integrated approach to improving outcomes of patients with sleep disorders – Canadian Sleep and Circadian Network (CSCN) Investments > €500k Canada Neurodegenerative disease in general 2016    

Relationship between serotonergic innervation, dopaminergic deficit and levodopa induced dopamine release patterns in PD treatment-related complications: a longitudinal imaging study Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Genetic Frontotemporal Dementia Initiative (GENFI) in Canada Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Cohort to illuminate Neurodegeneration, Genetics, Imaging Associations and Leukoaraiosis (CONGENIAL) Investments > €500k Canada Neurodegenerative disease in general 2016    

Virtual Reality based Spatial Memory Intervention for patients with Mild Cognitive Impairment Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Canadian Consortium on Neurodegeneration in Aging – Full Proposal Investments > €500k Canada Alzheimer’s disease & other dementias 2016    

Insights into Parkinson’s disease, Crohn’s disease, and leprosy: a common role for LRRK2 Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Aberrant NMDA receptor and synaptic signaling in vulnerability to neurodegeneration: Focus on Huntington disease Investments > €500k Canada Huntington’s disease 2016    

Functional Neuroimaging of dopamine systems: application to Parkinson’s Disease, addiction and obesity. Investments > €500k Canada Parkinson’s disease & PD-related disorders 2016    

Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease subtypes. Investments > €500k Canada Alzheimer’s disease & other dementias 2016